CSB Researcher Tina Iverson (Pharmacology) and colleagues have clarified part of the protein kinase MELK鈥檚 role in cell cycle signaling. MELK overexpression impacts survival and proliferation of multiple cancer types, so targeting it holds promise as a therapeutic strategy. .